Expanding CAR-T Cell Technology to Diverse Therapeutic Applications
Legal Citation
Summary of the Inventive Concept
This inventive concept leverages the core technology of CAR-T cells with TCM as the main active component to develop novel therapeutic solutions for neurodegenerative diseases, cancer relapse, autoimmune disorders, and personalized cancer vaccines.
Background and Problem Solved
The original patent disclosed a method for preparing CAR-T cells with TCM as the main active component, primarily focused on cancer treatment. However, the limitations of this technology lie in its narrow application scope. This inventive concept addresses the problem of limited therapeutic applications by exploring the potential of CAR-T cells with TCM in diverse fields.
Detailed Description of the Inventive Concept
The new claims expand the original patent's technology to four distinct areas: (1) treating neurodegenerative diseases by targeting specific disease antigens, (2) reducing cancer relapse in leukemia patients through long-term immune response induction, (3) detecting cancer biomarkers using engineered CAR-T cells, and (4) treating autoimmune disorders by inducing regulatory immune responses. Each application involves engineering CAR-T cells with TCM to recognize specific antigens or biomarkers, thereby inducing therapeutic responses.
Novelty and Inventive Step
The novelty of this inventive concept lies in the unexpected application of CAR-T cells with TCM to neurodegenerative diseases, cancer relapse, autoimmune disorders, and personalized cancer vaccines. The inventive step involves the recognition of the versatility of CAR-T cells with TCM and their potential to address unmet needs in diverse therapeutic areas.
Alternative Embodiments and Variations
Alternative embodiments of this inventive concept could include modifying the CAR-T cell's antigen recognition capabilities, using different types of T cells, or combining CAR-T cells with other immunotherapies. Variations may also involve adapting the technology to address specific disease subtypes or patient populations.
Potential Commercial Applications and Market
This inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, with potential applications in neurodegenerative disease treatment, cancer therapy, autoimmune disorder management, and personalized medicine. The market for these applications is substantial, with growing demands for innovative therapeutic solutions.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Immunotherapy, specifically CAR-T cell engineering and adaptive immune cell manipulation, with expertise in cell engineering, antigen targeting, and therapeutic cell modification
Person of Ordinary Skill (PHOSITA) Profile
A biomedical researcher or immunologist with advanced degree, experienced in genetic engineering of T cells, understanding of chimeric antigen receptor (CAR) design, and knowledge of cellular immunology techniques
Obviousness Rationale
A PHOSITA would recognize that the source patent's fundamental CAR-T cell technology with central memory T cells provides a versatile platform for targeting diverse disease antigens. The PTD's variations represent predictable extensions of the core technology by applying known CAR-T cell engineering principles to different therapeutic contexts. The modular nature of CAR design and the well-established understanding of T cell targeting mechanisms make these variations obvious to a skilled practitioner.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,572 |
|---|---|
| Title | Method for preparing CAR-T cell with TCM as main active component and use thereof |
| Assignee(s) | Xuanwu Hospital Capital Medical University |